Q-omics provides the consensus-scored INO80B profile across patient tissues and cancer cell-line models. INO80B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, INO80B is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, INO80B RNA expression shows 17,340 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where INO80B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INO80B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INO80B survival associations across molecular data types. INO80B RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INO80B RNA expression–survival associations across cancer types. High INO80B expression shows unfavorable associations in ACC and LIHC, but favorable associations in UVM, ESCA, BRCA and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for INO80B RNA expression.
This table summarizes INO80B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for INO80B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INO80B shows higher tumor expression in KIRC, COAD, LIHC, HNSC, LUSC and STAD. The KIRC box plot shows higher INO80B RNA expression in tumor versus normal tissue (log2 FC = +0.840, t-test p < 0.001).
This table shows molecular features associated with INO80B in patient tissues and cancer cell lines. In patient samples, INO80B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, INO80B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
